Barclays upgrades Sun Pharma to overweight
Barclays
upgrades Sun Pharma to overweight from equalweight earlier. Risk reward
ratio is now favorable for investors. Multiple negatives are priced into
the valuation. Base case suggests a 27 per cent upside potential.
Bear-case scenario implies a 18 per cent downside potential.